Drug Trial Radar · NCT05928390
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
93
Actual
Start
Jan 4, 2024
Primary completion
Oct 29, 2026
Study completion Oct 29, 2026
Sponsor
- Lead sponsor
- RECORDATI GROUPIndustry
- Sponsor type
- Industry
- First posted
- Jul 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods * 19 weeks for the Core Phase. It is composed of: * a Screening period: a maximum of 3 weeks * a Run-in period (no treatment): 4 weeks * a Blinded Treatment Phase: 12 weeks * 36 weeks Extension Phase = an open-label Treatment period * 4 weeks for the safety follow-up period (without any treatment).
Conditions
- Post-Bariatric Hypoglycemia
Interventions
Pasireotide DiaspartateDrug
Injectable ampoules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of the efficacy of pasireotide s.c. on blood glucose concentration during an MMTT in patients with PBH after 12 weeks of treatment.Time frame: at baseline and at 12 weeks
Locations
29 sites in 6 countries. Site status is shown where the registry gives one.
Stanford University School of Medicine, Endocrinology, 800 Welch Road,
Palo Alto, California
Northwestern University - Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
NOLA Care
Metairie, Louisiana
Velocity Clinical Research - Annapolis
Annapolis, Maryland
Joslin Diabetes CenterJoslin Diabetes Center, One Joslin Place
Boston, Massachusetts
Mayo Clinic - Rochester, 200 First Street, SW, 55905
Rochester, Minnesota
Montefiore Medical Center, 111 E 210th Street,
The Bronx, New York
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr,
San Antonio, Texas
University of Wisconsin Health W. E. Clinic END, 451 Junction Rd,
Madison, Wisconsin
Universitaire Ziekenhuizen Leuven, Department of Gastroenterology and Hepatology,Herestraat 49
Leuven, Belgium
AP-HP Hopital Europeen Georges Pompidou, 20, rue Leblanc,
Paris, France
HCL Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Hopital Rangueil, Attachée de Recherche Clinique, Centre Investigation Clinique, CHU, Cedex 9, France
Toulouse, France
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola
Bologna, Italy
Azienda Ospedale - Università Padova, Clinica Medica 3, Via Giustiniani, 2,
Padova, Italy
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Palermo, Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, L.go Gemelli 8
Rome, Italy
Hospital Universitario Vall d'Hebron, Passeig Vall d´Hebron 119-129, Spain
Barcelona, Spain
Hospital Clinic Barcelona, Lipid Clinic End, Nutr. Service Hospital Clinic, C. Villarroel, 170,
Barcelona, Spain
Hospital Germans Trias i Pujol
Barcelona, Spain
Hospital Universitario Reina Sofia
Córdoba, Spain
Hospital Universitari de Girona Dr. Josep Trueta
Girona, Spain
Hospital Clinico San Carlos, C/ Prof Martin Lagos s/n, Spain
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
North Bristol NHS Trust
Bristol, United Kingdom
King's College Hospital NHS Foundation Trust, Denmark Hill, SE5 9RS
London, United Kingdom
Hammersmith Hospital
London, United Kingdom
Guy's Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.